3月11日 - ** 制药商Pacira BioSciences PCRX.O股价盘前上涨2%至22.78美元
** 激进投资者 DOMA Perpetual表示，它已向PCRX董事会提名了三名董事，并正在寻求罢免首席执行官李（Frank Lee），理由是该公司多年来财务业绩不佳。
** 称 Pacira 的股价在 10 年内下跌了 56%，在 5 年内下跌了 68%，在 李任内下跌了 30%
** 补充说 Pacira 公司规模太小，无法有效销售其非阿片类手术止痛药 Exparel，并敦促启动正式出售程序
** 批评 PCRX 董事会批准高管高薪并将总部迁往旧金山
** 2025 年股价上涨约 37%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.